The total return over the past 12 months is +11.69% vs. +16.94% for the S&P 500. So far it's up +6.94% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +11.69% | +36.31% | +7.40% | +27.41% | N/A | N/A |
| Total Return CAGR | +11.69% | +36.31% | +7.40% | +27.41% | N/A | N/A |
| Revenue CAGR | +126.35% | +112.33% | +189.92% | +67.10% | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Ascendis Pharma A/S (ASND)
| Year | Start price | End price | ASND Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $213.24 | $228.03 | +6.94% | +14.51% | (7.57%) |
| 2025 | $137.67 | $213.24 | +54.89% | +17.72% | +37.17% |
| 2024 | $125.95 | $137.67 | +9.31% | +24.89% | (15.58%) |
| 2023 | $122.13 | $125.95 | +3.13% | +26.19% | (23.06%) |
| 2022 | $134.53 | $122.13 | (9.22%) | (18.17%) | +8.95% |
| 2021 | $166.78 | $134.53 | (19.34%) | +28.74% | (48.08%) |
| 2020 | $139.12 | $166.78 | +19.88% | +18.37% | +1.51% |
| 2019 | $62.65 | $139.12 | +122.06% | +31.22% | +90.84% |
| 2018 | $40.06 | $62.65 | +56.39% | (4.56%) | +60.95% |
| 2017 | $20.24 | $40.06 | +97.92% | +21.70% | +76.22% |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
